Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)

Exclusion Criteria

• •Presence of diplopia (indication of immediate blood patch)
• •Contraindication to ACTH or Synacthène® (unbalanced hypertension, uncontrolled diabetes, uncontrolled psychosis, infectious viral disease state or evolving)
• •Processing of Torsade de Pointe provider (astenizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine)
• •Live vaccine in the months prior to inclusion
• •Hypersensitivity to Synacthène®
• •Patient who have previously received Synacthène® after delivery
• •Contraindication to blood patch (fever or leukocytosis, HIV or HCV patient)
• •Eclampsia or preeclampsia during this pregnancy
• •Patient who have received prophylactic blood patch (at diagnosis of Accidental Dural Puncture)
• •Minor under 18 or protected
• •Psychological disorders do not allowing informed consent
• •Refusal of participation in the study or participation in another ongoing interventional study
• •Withdrawal of consent